Laboratory Diagnosis of Lyme Disease: Advances and Challenges

Infectious Disease Clinics of North America

Volumn 29, Issue 2, 2015, Pages 295-307

  Marques, Adriana R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Borrelia burgdorferi; Laboratory diagnosis; Lyme disease; Serology

Indexed keywords

CXCL13 CHEMOKINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BORRELIA BURGDORFERI; ELISA KIT; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; LABORATORY DIAGNOSIS; LYME DISEASE; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; XENODIAGNOSIS; ISOLATION AND PURIFICATION; LABORATORY TEST; PROCEDURES; SEROLOGY; STANDARDS;

BORRELIA BURGDORFERI; CLINICAL LABORATORY TECHNIQUES; HUMANS; LYME DISEASE; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS;

EID: 84929610683     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2015.02.005     Document Type: Review

References (100)

1. CDC. How many people get Lyme disease? 2013. Available at: Accessed September 17, 2014. http://www.cdc.gov/lyme/stats/humanCases.html.
2. Tilly K., Rosa P.A., Stewart P.E. Biology of infection with Borrelia burgdorferi. Infect Dis Clin North Am 2008, 22:217-234. v.
3. Di L., Pagan P.E., Packer D., et al. BorreliaBase: a phylogeny-centered browser of Borrelia genomes. BMC Bioinformatics 2014, 15:233.
4. Radolf J.D., Caimano M.J., Stevenson B., et al. Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat Rev Microbiol 2012, 10:87-99.
5. Franke J., Hildebrandt A., Dorn W. Exploring gaps in our knowledge on Lyme borreliosis spirochaetes-updates on complex heterogeneity, ecology, and pathogenicity. Ticks Tick Borne Dis 2013, 4:11-25.
6. Stanek G., Wormser G.P., Gray J., et al. Lyme borreliosis. Lancet 2012, 379:461-473.
7. Wormser G.P., Brisson D., Liveris D., et al. Borrelia burgdorferi genotype predicts the capacity for hematogenous dissemination during early Lyme disease. JInfect Dis 2008, 198:1358-1364.
8. Hanincova K., Mukherjee P., Ogden N.H., et al. Multilocus sequence typing of Borrelia burgdorferi suggests existence of lineages with differential pathogenic properties in humans. PLoS One 2013, 8:e73066.
9. Steere A.C., Bartenhagen N.H., Craft J.E., et al. The early clinical manifestations of Lyme disease. Ann Intern Med 1983, 99:76-82.
10. Nadelman R.B., Nowakowski J., Forseter G., et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med 1996, 100:502-508.
11. Strle F., Nadelman R.B., Cimperman J., et al. Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia. Ann Intern Med 1999, 130:32-36.
12. Kindstrand E., Nilsson B.Y., Hovmark A., et al. Peripheral neuropathy in acrodermatitis chronica atrophicans - a late Borrelia manifestation. Acta Neurol Scand 1997, 95:338-345.
13. Halperin J.J., Logigian E.L., Finkel M.F., et al. Practice parameters for the diagnosis of patients with nervous system Lyme borreliosis (Lyme disease).Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996, 46:619-627.
14. Logigian E.L., Kaplan R.F., Steere A.C. Chronic neurologic manifestations of Lyme disease. NEngl J Med 1990, 323:1438-1444.
15. Steere A.C., Schoen R.T., Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987, 107:725-731.
16. Steere A.C., Malawista S.E., Hardin J.A., et al. Erythema chronicum migrans and Lyme arthritis. The enlarging clinical spectrum. Ann Intern Med 1977, 86:685-698.
17. Steere A.C., Malawista S.E., Snydman D.R., et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum 1977, 20:7-17.
18. Tee S.I., Martínez-Escanamé M., Zuriel D., et al. Acrodermatitis chronica atrophicans with pseudolymphomatous infiltrates. Am J Dermatopathol 2013, 35:338-342.
19. Mullegger R.R., Glatz M. Skin manifestations of Lyme borreliosis: diagnosis and management. Am J Clin Dermatol 2008, 9:355-368.
20. De Koning J., Bosma R.B., Hoogkamp-Korstanje J.A. Demonstration of spirochaetes in patients with Lyme disease with a modified silver stain. JMed Microbiol 1987, 23:261-267.
21. de Koning J., Tazelaar D.J., Hoogkamp-Korstanje J.A., et al. Acrodermatitis chronica atrophicans: a light and electron microscopic study. JCutan Pathol 1995, 22:23-32.
22. Johnston Y.E., Duray P.H., Steere A.C., et al. Lyme arthritis. Spirochetes found in synovial microangiopathic lesions. Am J Pathol 1985, 118:26-34.
23. Duray P.H. Clinical pathologic correlations of Lyme disease. Rev Infect Dis 1989, 11(Suppl 6):S1487-S1493.
24. Eisendle K., Grabner T., Zelger B. Focus floating microscopy: "gold standard" for cutaneous borreliosis?. Am J Clin Pathol 2007, 127:213-222.
25. Aberer E., Kersten A., Klade H., et al. Heterogeneity of Borrelia burgdorferi in the skin. Am J Dermatopathol 1996, 18:571-579.
26. Aberer E., Klade H., Hobisch G. Aclinical, histological, and immunohistochemical comparison of acrodermatitis chronica atrophicans and morphea. Am J Dermatopathol 1991, 13:334-341.
27. Coyle P.K., Schutzer S.E., Deng Z., et al. Detection of Borrelia burgdorferi-specific antigen in antibody-negative cerebrospinal fluid in neurologic Lyme disease. Neurology 1995, 45:2010-2015.
28. Klempner M.S., Schmid C.H., Hu L., et al. Intralaboratory reliability of serologic and urine testing for Lyme disease. Am J Med 2001, 110:217-219.
29. Pollack R.J., Telford S.R., Spielman A. Standardization of medium for culturing Lyme disease spirochetes. JClin Microbiol 1993, 31:1251-1255.
30. Ruzic-Sabljic E., Lotric-Furlan S., Maraspin V., et al. Comparison of isolation rate of Borrelia burgdorferi sensu lato in MKP and BSK-II medium. Int J Med Microbiol 2006, 296(Suppl 40):267-273.
31. Liveris D., Schwartz I., Bittker S., et al. Improving the yield of blood cultures from patients with early Lyme disease. JClin Microbiol 2011, 49:2166-2168.
32. Xu G., Wesker J., White C., et al. Detection of heterogeneity of Borrelia burgdorferi in Ixodes ticks by culture-dependent and culture-independent methods. JClin Microbiol 2013, 51:615-617.
33. Nadelman R.B., Nowakowski J., Forseter G., et al. Failure to isolate Borrelia burgdorferi after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: report of a prospective study. Am J Med 1993, 94:583-588.
34. Picken M.M., Picken R.N., Han D., et al. Atwo year prospective study to compare culture and polymerase chain reaction amplification for the detection and diagnosis of Lyme borreliosis. Mol Pathol 1997, 50:186-193.
35. Liveris D., Wang G., Girao G., et al. Quantitative detection of Borrelia burgdorferi in 2-millimeter skin samples of erythema migrans lesions: correlation of results with clinical and laboratory findings. JClin Microbiol 2002, 40:1249-1253.
36. Liveris D., Schwartz I., McKenna D., et al. Comparison of five diagnostic modalities for direct detection of Borrelia burgdorferi in patients with early Lyme disease. Diagn Microbiol Infect Dis 2012, 73:243-245.
37. O'Rourke M., Traweger A., Lusa L., et al. Quantitative detection of Borrelia burgdorferi sensu lato in erythema migrans skin lesions using internally controlled duplex real time PCR. PLoS One 2013, 8:e63968.
38. Cerar T., Ruzic-Sabljic E., Glinsek U., et al. Comparison of PCR methods and culture for the detection of Borrelia spp. in patients with erythema migrans. Clin Microbiol Infect 2008, 14:653-658.
39. Ruzic-Sabljic E., Maraspin V., Cimperman J., et al. Comparison of isolation rate of Borrelia burgdorferi sensu lato in two different culture media, MKP and BSK-H. Clin Microbiol Infect 2014, 20:636-641.
40. Coulter P., Lema C., Flayhart D., et al. Two-year evaluation of Borrelia burgdorferi culture and supplemental tests for definitive diagnosis of Lyme disease. JClin Microbiol 2005, 43:5080-5084.
41. Ogrinc K., Lotrič-Furlan S., Maraspin V., et al. Suspected early Lyme neuroborreliosis in patients with erythema migrans. Clin Infect Dis 2013, 57:501-509.
42. Li X., McHugh G.A., Damle N., et al. Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or Lyme arthritis. Arthritis Rheum 2011, 63:2238-2247.
43. Strle F., Lusa L., Ružić-Sabljić E., et al. Clinical characteristics associated with Borrelia burgdorferi sensu lato skin culture results in patients with erythema migrans. PLoS One 2013, 8:e82132.
44. Maraspin V., Ogrinc K., Ruzic-Sabljic E., et al. Isolation of Borrelia burgdorferi sensu lato from blood of adult patients with borrelial lymphocytoma, Lyme neuroborreliosis, Lyme arthritis and acrodermatitis chronica atrophicans. Infection 2011, 39:35-40.
45. Nowakowski J., McKenna D., Nadelman R.B., et al. Blood cultures for patients with extracutaneous manifestations of Lyme disease in the United States. Clin Infect Dis 2009, 49:1733-1735.
46. Cerar T., Ogrinc K., Lotric-Furlan S., et al. Diagnostic value of cytokines and chemokines in Lyme neuroborreliosis. Clin Vaccine Immunol 2013, 20:1578-1584.
47. Strle F., Ruzic-Sabljic E., Cimperman J., et al. Comparison of findings for patients with Borrelia garinii and Borrelia afzelii isolated from cerebrospinal fluid. Clin Infect Dis 2006, 43:704-710.
48. Cerar T., Ogrinc K., Cimperman J., et al. Validation of cultivation and PCR methods for diagnosis of Lyme neuroborreliosis. JClin Microbiol 2008, 46:3375-3379.
49. Wormser G.P., Nadelman R.B., Schwartz I. The amber theory of Lyme arthritis: initial description and clinical implications. Clin Rheumatol 2012, 31:989-994.
50. Johnson B.J., Pilgard M.A., Russell T.M. Assessment of new culture method for detection of Borrelia species from serum of Lyme disease patients. JClin Microbiol 2014, 52:721-724.
51. Sapi E., Pabbati N., Datar A., et al. Improved culture conditions for the growth and detection of Borrelia from human serum. Int J Med Sci 2013, 10:362-376.
52. Phillips S.E., Mattman L.H., Hulinska D., et al. Aproposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treated. Infection 1998, 26:364-367.
53. Marques A.R., Stock F., Gill V. Evaluation of a new culture medium for Borrelia burgdorferi. JClin Microbiol 2000, 38:4239-4241.
54. Tilton R.C., Barden D., Sand M. Culture Borrelia burgdorferi. JClin Microbiol 2001, 39:2747.
55. Eshoo M.W., Crowder C.C., Rebman A.W., et al. Direct molecular detection and genotyping of Borrelia burgdorferi from whole blood of patients with early Lyme disease. PLoS One 2012, 7:e36825.
56. Nocton J.J., Dressler F., Rutledge B.J., et al. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. NEngl J Med 1994, 330:229-234.
57. Persing D.H., Rutledge B.J., Rys P.N., et al. Target imbalance: disparity of Borrelia burgdorferi genetic material in synovial fluid from Lyme arthritis patients. JInfect Dis 1994, 169:668-672.
58. Mygland A., Ljøstad U., Fingerle V., et al. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 2010, 17:8-16. e1-4.
59. Hinckley A.F., Connally N.P., Meek J.I., et al. Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis 2014, 59:676-681.
60. CDC Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995, 44:590-591.
61. Fallon B.A., Pavlicova M., Coffino S.W., et al. Acomparison of Lyme disease serologic test results from four laboratories in patients with persistent symptoms after antibiotic treatment. Clin Infect Dis 2014, 59(12):1705-1710.
62. Barclay S.S., Melia M.T., Auwaerter P.G. Misdiagnosis of late-onset Lyme arthritis by inappropriate use of Borrelia burgdorferi immunoblot testing with synovial fluid. Clin Vaccin Immunol 2012, 19:1806-1809.
63. Gomes-Solecki M.J., Dunn J.J., Luft B.J., et al. Recombinant chimeric Borrelia proteins for diagnosis of Lyme disease. JClin Microbiol 2000, 38:2530-2535.
64. Branda J.A., Aguero-Rosenfeld M.E., Ferraro M.J., et al. 2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. Clin Infect Dis 2010, 50:20-26.
65. Marques A.R., Martin D.S., Philipp M.T. Evaluation of the C6 peptide enzyme-linked immunosorbent assay for individuals vaccinated with the recombinant OspA vaccine. JClin Microbiol 2002, 40:2591-2593.
66. Bacon R.M., Biggerstaff B.J., Schriefer M.E., et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. JInfect Dis 2003, 187:1187-1199.
67. Philipp M.T., Marques A.R., Fawcett P.T., et al. C6 test as an indicator of therapy outcome for patients with localized or disseminated Lyme borreliosis. JClin Microbiol 2003, 41:4955-4960.
68. Burbelo P.D., Issa A.T., Ching K.H., et al. Rapid, simple, quantitative, and highly sensitive antibody detection for Lyme disease. Clin Vaccine Immunol 2010, 17:904-909.
69. Wormser G.P., Schriefer M., Aguero-Rosenfeld M.E., et al. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis 2013, 75:9-15.
70. Branda J.A., Strle F., Strle K., et al. Performance of United States serologic assays in the diagnosis of Lyme borreliosis acquired in Europe. Clin Infect Dis 2013, 57:333-340.
71. Branda J.A., Linskey K., Kim Y.A., et al. Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis 2011, 53:541-547.
72. Steere A.C., McHugh G., Damle N., et al. Prospective study of serologic tests for Lyme disease. Clin Infect Dis 2008, 47:188-195.
73. Wormser G.P., Tang A.T., Schimmoeller N.R., et al. Utility of serodiagnostics designed for use in the United States for detection of Lyme borreliosis acquired in Europe and vice versa. Med Microbiol Immunol 2014, 203:65-71.
74. Gomes-Solecki M.J., Wormser G.P., Schriefer M., et al. Recombinant assay for serodiagnosis of Lyme disease regardless of OspA vaccination status. JClin Microbiol 2002, 40:193-197.
75. Porwancher R.B., Hagerty C.G., Fan J., et al. Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10-IgM antibodies: improving test performance through bioinformatics. Clin Vaccine Immunol 2011, 18:851-859.
76. Arnaboldi P.M., Seedarnee R., Sambir M., et al. Outer surface protein C peptide derived from Borrelia burgdorferi sensu stricto as a target for serodiagnosis of early Lyme disease. Clin Vaccine Immunol 2013, 20:474-481.
77. Mathiesen M.J., Christiansen M., Hansen K., et al. Peptide-based OspC enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis. JClin Microbiol 1998, 36:3474-3479.
78. Wormser G.P., Nowakowski J., Nadelman R.B., et al. Impact of clinical variables on Borrelia burgdorferi-specific antibody seropositivity in acute-phase sera from patients in North America with culture-confirmed early Lyme disease. Clin Vaccine Immunol 2008, 15:1519-1522.
79. Tuuminen T., Hedman K., Soderlund-Venermo M., et al. Acute parvovirus B19 infection causes nonspecificity frequently in Borrelia and less often in Salmonella and Campylobacter serology, posing a problem in diagnosis of infectious arthropathy. Clin Vaccine Immunol 2011, 18:167-172.
80. Wormser G.P., Horowitz H.W., Nowakowski J., et al. Positive Lyme disease serology in patients with clinical and laboratory evidence of human granulocytic ehrlichiosis. Am J Clin Pathol 1997, 107:142-147.
81. Seriburi V., Ndukwe N., Chang Z., et al. High frequency of false positive IgM immunoblots for Borrelia burgdorferi in clinical practice. Clin Microbiol Infect 2012, 18:1236-1240.
82. Wormser G.P., Levin A., Soman S., et al. Comparative cost-effectiveness of two-tiered testing strategies for serodiagnosis of Lyme disease with noncutaneous manifestations. JClin Microbiol 2013, 51:4045-4049.
83. Kalish R.A., McHugh G., Granquist J., et al. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis 2001, 33:780-785.
84. Peltomaa M., McHugh G., Steere A.C. Persistence of the antibody response to the VlsE sixth invariant region (IR6) peptide of Borrelia burgdorferi after successful antibiotic treatment of Lyme disease. JInfect Dis 2003, 187:1178-1186.
85. Chandra A., Wormser G.P., Marques A.R., et al. Anti-Borrelia burgdorferi antibody profile in post-Lyme disease syndrome. Clin Vaccine Immunol 2011, 18:767-771.
86. Chandra A., Latov N., Wormser G.P., et al. Epitope mapping of antibodies to VlsE protein of Borrelia burgdorferi in post-Lyme disease syndrome. Clin Immunol 2011, 141:103-110.
87. Philipp M.T., Wormser G.P., Marques A.R., et al. Adecline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme Borreliosis. Clin Diagn Lab Immunol 2005, 12:1069-1074.
88. Djukic M., Schmidt-Samoa C., Lange P., et al. Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis. JNeurol 2012, 259:630-636.
89. Stanek G., Lusa L., Ogrinc K., et al. Intrathecally produced IgG and IgM antibodies to recombinant VlsE, VlsE peptide, recombinant OspC and whole cell extracts in the diagnosis of Lyme neuroborreliosis. Med Microbiol Immunol 2013, 203(2):125-132.
90. Henningsson A.J., Christiansson M., Tjernberg I., et al. Laboratory diagnosis of Lyme neuroborreliosis: a comparison of three CSF anti-Borrelia antibody assays. Eur J Clin Microbiol Infect Dis 2013, 33(5):797-803.
91. van Burgel N.D., Brandenburg A., Gerritsen H.J., et al. High sensitivity and specificity of the C6-peptide ELISA on cerebrospinal fluid in Lyme neuroborreliosis patients. Clin Microbiol Infect 2011, 17:1495-1500.
92. Cerar T., Ogrinc K., Strle F., et al. Humoral immune responses in patients with Lyme neuroborreliosis. Clin Vaccine Immunol 2010, 17:645-650.
93. Steere A.C., Berardi V.P., Weeks K.E., et al. Evaluation of the intrathecal antibody response to Borrelia burgdorferi as a diagnostic test for Lyme neuroborreliosis. JInfect Dis 1990, 161:1203-1209.
94. Halperin J.J., Golightly M. Lyme borreliosis in Bell's palsy. long island neuroborreliosis collaborative study group. Neurology 1992, 42:1268-1270.
95. Smouha E.E., Coyle P.K., Shukri S. Facial nerve palsy in Lyme disease: evaluation of clinical diagnostic criteria. Am J Otol 1997, 18:257-261.
96. Martin R., Martens U., Sticht-Groh V., et al. Persistent intrathecal secretion of oligoclonal, Borrelia burgdorferi-specific IgG in chronic meningoradiculomyelitis. JNeurol 1988, 235:229-233.
97. Hammers-Berggren S., Hansen K., Lebech A.M., et al. Borrelia burgdorferi-specific intrathecal antibody production in neuroborreliosis: a follow-up study. Neurology 1993, 43:169-175.
98. Bremell D., Mattsson N., Edsbagge M., et al. Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection. BMC Neurol 2013, 13:2.
99. Schmidt C., Plate A., Angele B., et al. Aprospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology 2011, 76:1051-1058.
100. Marques A., Brown M.R., Fleisher T.A. Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls. Clin Vaccine Immunol 2009, 16:1249-1250.